பரம்பரை மரபியல்: தற்போதைய ஆராய்ச்சி

சுருக்கம்

A Novel Versatile Antibody-Drug Conjugate for Cancer Therapy

Chuan-Lung Hsu

Abstract
Antibody drug forms (ADCs), a promising cutting edge counter acting agent drug, join tumor particularity with exceptionally powerful cytotoxic payload for improve remedial adequacy in disease treatment. Nonetheless, because of the assembling issues and delivering heterogeneous results of irregular formation of ADCs, here we report a profoundly effective glycogengineering innovation by utilizing a GnT-I (N-Acetyl glucosamine transferase I) and a GnT-II (N-Acetyl glucosamine transferase II) as proteins to form a tri-mannosyl center immunizer and produce an adaptable ADC. Our results show that a homogenous tri-mannosyl Herceptin-2(GlcNAc-triazole-DBCO-(PEG)4-DM1)- 2(GlcNAc-triazole-DBCO-PEG4-Vc-PAB-(PEG)2-Duocarmycin) is made with the change efficiency over 90% and half recovery rate.The outcomes demonstrate that the tri-mannosyl ADC has not just with exceptionally strong cytotoxicity (IC50<1.2 nM) than Kadcyla, yet additionally with better enemy of tumor development movement in BT-474 and N87 xenograft (TGI>90%)